|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 利培酮联合小剂量阿立哌唑对精神分裂症患者血清神经递质、糖脂代谢及BMI的影响显示文摘目的:探讨利培酮联合小剂量阿立哌唑治疗对精神分裂症患者血清神经递质、糖脂代谢及体质量指数(BMI)的影响。方法:选取2016年1月~2018年10月期间我院收治的80例精神分裂症患者,根据随机数字表法将患者分为对照组(n=40)和研究组(n=40),对照组予以利培酮治疗,研究组在对照组基础上联合小剂量阿立哌唑治疗,比较两组患者疗效、阳性和阴性症状评定量表(PANSS)评分、血清神经递质[多巴胺、去甲肾上腺素(NE)、5-羟吲哚乙酸(5-HIAA)]和糖脂代谢[血糖(FPG)、总胆固醇(TC)、三酰甘油(TG)],记录两组治疗期间不良反应情况。结果:研究组治疗4周后临床总有效率为97.50%(39/40),高于对照组的82.50%(33/40)(P<0.05)。两组治疗4周后PANSS中的阴性症状评分、阳性症状评分、一般病理评分、总分、FPG、TC、TG及血清多巴胺水平均较治疗前下降,且研究组低于对照组(P<0.05)。两组患者治疗4周后血清NE、5-HIAA水平均升高,且研究组高于对照组(P<0.05)。两组患者治疗4周后BMI均略有增加,但差异无统计学意义(均P>0.05)。研究组、对照组不良反应总发生率分别为15.00%(6/40)、12.50%(5/40),二者比较无差异(P>0.05)。结论:利培酮联合小剂量阿立哌唑治疗精神分裂症患者可提高其临床疗效,可有效改善血清神经递质水平,对机体糖脂代谢和BMI影响轻微,且用药安全性较好。 | 蒋秀兰 戴福强 秦淑国 胡康 王凌云 | 2020 | 现代生物医学进展2020，20，7： | 24 |
| 2 | 阿立哌唑治疗氨磺必利诱导的高催乳素血症的疗效及最佳有效血药浓度范围研究显示文摘目的:探讨阿立哌唑治疗氨磺必利诱导的高催乳素血症的疗效及最佳有效血药浓度范围。方法:选取佛山市顺德区伍仲珮纪念医院2019年收治的精神分裂症患者88例,采用随机数字表法分为氨磺必利组(给予氨磺必利治疗)和联合组(给予阿立哌唑+氨磺必利治疗)。观察两组患者治疗前后阳性和阴性症状量表(positive and negative syndrome scale,PANSS)评分、雌二醇(E2)水平,并结合血药浓度结果比较两组患者治疗前后体内催乳素(PRL)水平的差异。结果:治疗12周后,联合组、氨磺必利组患者PANSS评分分别为(69.88±7.393)、(69.77±8.815)分,差异无统计学意义(P>0.05);联合组、氨磺必利组患者E2水平分别为(325.94±107.721)、(346.03±125.826)pmol/L,差异无统计学意义(P>0.05);联合组患者血清PRL水平为(15.17±20.165)ng/ml,明显低于氨磺必利组的(110.40±31.224)ng/ml,差异有统计学意义(P<0.05)。治疗第12周时,联合组患者阿立哌唑的血药浓度为(236.97±99.227)ng/ml。结论:阿立哌唑可有效改善氨磺必利引起的PRL水平升高,且疗效明确,阿立哌唑的最佳有效血药浓度为150~350 ng/ml。 | 于志军 林述胜 吴海根 蔡思敏 胡贵先 王俊荣 李春阳 | 2020 | 中国医院用药评价与分析2020，20，8： | 8 |
| 3 | Effects of ketamine in electroconvulsive therapy for major depressive disorder:meta-analysis of randomised controlled trials显示文摘Background The use of ketamine in electroconvulsive therapy(ECT)has been examined in the treatment of major depressive disorder(MDD);however,there has been no systematic review and meta-analysis of related randomised controlled trials(RCTs).Aim To examine the efficacy and safety of ketamine augmentation of ECT in MDD treatment.Methods Two reviewers searched Chinese(China National Knowledge Infrastructure and Wanfang)and English(PubMed,PsycINFO,Embase and Cochrane Library)databases from their inception to 23 July 2019.The included studies'bias risk was evaluated using the Cochrane risk of bias assessment tool.The primary outcome of this metaanalysis was improved d印ressive symptoms at day 1 after a single ECT treatment session.Data were pooled to calculate the standardised mean difference and risk ratio with their 95%CIs using RevMan V.5.3.We used the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)approach to assess the whole quality of evidence.Results Four RCTs(n=239)compared ketamine alone or ketamine plus propofol(n=149)versus propofol alone(n=90)in patients with MDD who underwent a single ECT session.Three RCTs were considered as unclear risk with respect to random sequence generation using the Cochrane risk of bias.Compared with propofol alone,ketamine alone and the combination of ketamine and propofol had greater efficacy in the treatment of depressive symptoms at days 1,3 and 7 after a single ECT session.Moreover,compared with propofol alone,ketamine alone and the combination of ketamine and propofol were significantly associated with increased seizure duration and seizure energy index.Compared with propofol,ketamine alone was significantly associated with increased opening-eye time.Based on the GRADE approach,the evidence level of primary and secondary outcomes ranged from very low(26.7%,4/15)to‘low'(73.3%,11/15).Conclusion Compared with propofol,there were very low or low evidence levels showing that ketamine alone and the combination of ketamine and propofol appeared to rapidly improve depressive symptoms of patients with MDD undergoing a single ECT session.There is a need for highquality RCTs. | Xiao-Mei Li Zhan-Ming Shi Pei-Jia Wang Hua Hu | 2020 | General Psychiatry2020，33，3： | 1 |
| 4 | 逍遥丸治疗抗精神病药物所致女性精神分裂症患者高泌乳素血症的疗效和安全性:一项Meta分析显示文摘目的 探讨逍遥丸治疗抗精神病药物所致女性精神分裂症患者高泌乳素血症的疗效和安全性.方法 三位研究者系统检索中文数据库(中国知网、万方数据库)和英文数据库(PubMed、Cochrane Library、EMBASE和PsycINFO),纳入关于逍遥丸治疗抗精神病药物所致精神分裂症患者高泌乳素血症的随机对照研究(Randomized Controlled Trials,RCTs),并采用RevMan,5.3软件对结果进行Meta分析.结果 本项Meta分析共纳入3篇RCTs,共计210例女性精神分裂症患者.Meta分析结果显示:逍遥丸组血清泌乳素(Prolactin,PRL)水平明显低于对照组[标准化均数差(Standard Mean Difference,SMD)=-2.71,95%置信区间(Confidence Interval,CI):-3.72~-1.69,P<0.00001],差异有统计学意义;逍遥丸组阳性与阴性症状量表总分稍高于对照组(SMD=0.04,95%CI:-0.23~0.31,P=0.78),差异无统计学意义.结论 逍遥丸可有效降低抗精神病药物所致女性精神分裂症患者高泌乳素血症的血清PRL水平,改善高泌乳素血症诱导的相关症状. | 覃振捐 蓝贤俊 刘其蔓 蔡东滨 韦鑫 黄雄 郑伟 | 2023 | 国际精神病学杂志2023，50，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员